Luke Clauson serves as Vice President - Research &Development and Manufacturing of the Company. He founded a medical device-focused engineering development company, Innovative Drive Corporation, that has helped businesses of all sizes conceptualize and bring dozens of products to market, including several in ophthalmology, in 2004 and has been serving as its President since then. Mr. Clauson has been the President and a director of Inspire Products, Inc. since 2012 and also serves on the board of directors of Mimicmotion, Inc. From 2016 until 2018, he was Chief Operating Officer of ianTECH, Inc. From 2009 to 2016, Mr. Clauson was Vice President, Research & Development and Operations at Transcend Medical. He started his engineering career at Cardica, Inc. (now Dex Liquidating Co.), where he ultimately directed product development for the core anastomotic business. Mr. Clauson has extensive experience in designing, validating, achieving regulatory approval and scaling for commercialization with multiple products. He holds a B.Sc. in mechanical engineering from the University of California, Davis.
Luke Clauson is 42, he's been the Vice President - Research &Development and Manufacturing of Eyenovia Inc since 2017. There are 12 older and no younger executives at Eyenovia Inc. The oldest executive at Eyenovia Inc is Ernest Mario, 81, who is the Independent Director.
Luke's mailing address filed with the SEC is C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400, NEW YORK, NY, 10017.
Over the last 7 years, insiders at Eyenovia Inc have traded over $1,275,000 worth of Eyenovia Inc stock and bought 6,072,235 units worth $17,599,075 . The most active insiders traders include Ernest Mario, Stuart M. Grant a Fredric N Eshelman. On average, Eyenovia Inc executives and independent directors trade stock every 31 days with the average trade being worth of $49,678. The most recent stock trade was executed by Michael M Rowe on 28 August 2024, trading 27,071 units of EYEN stock currently worth $14,077.
eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.
Eyenovia Inc executives and other stock owners filed with the SEC include: